Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Cl.Mg.6H2O |
Molecular Weight | 203.303 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.O.[Mg++].[Cl-].[Cl-]
InChI
InChIKey=DHRRIBDTHFBPNG-UHFFFAOYSA-L
InChI=1S/2ClH.Mg.6H2O/h2*1H;;6*1H2/q;;+2;;;;;;/p-2
Molecular Formula | Cl |
Molecular Weight | 35.453 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/dosage/magnesium-lactate.htmlhttps://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.ncbi.nlm.nih.gov/pubmed/351265https://www.drugs.com/ppa/magnesium-chloride.htmlhttp://www.db-pharma.com/anglais/49.pdfhttps://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1http://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfdoi: 10.1081/SCC-120022479DOI: 10.2903/j.efsa.2008.883https://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640Curator's Comment: description was created based on several sources, including:
https://www.blackmores.com.au/products/magmin | https://www.ncbi.nlm.nih.gov/pubmed/25262412 |http://www.webstercare.com.au/files/continuing_education/wc_continuing_edu_dec2011.pdf
Sources: https://www.drugs.com/dosage/magnesium-lactate.htmlhttps://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.ncbi.nlm.nih.gov/pubmed/351265https://www.drugs.com/ppa/magnesium-chloride.htmlhttp://www.db-pharma.com/anglais/49.pdfhttps://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1http://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfdoi: 10.1081/SCC-120022479DOI: 10.2903/j.efsa.2008.883https://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640
Curator's Comment: description was created based on several sources, including:
https://www.blackmores.com.au/products/magmin | https://www.ncbi.nlm.nih.gov/pubmed/25262412 |http://www.webstercare.com.au/files/continuing_education/wc_continuing_edu_dec2011.pdf
Magnesium diamide is used as a chemical intermediate. Magnesium diamide is spontaneously combustible. It is toxic by inhalation. Skin or eye contact may cause severe burns.
CNS Activity
Sources: https://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQCDOI: 10.1002/0471238961.0218151310010311.a02
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolic effects of prolonged intravenous administration of magnesium lactate to the normal human. | 1958 Sep 23 |
|
Struvite stones. | 1978 May |
|
Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides. | 1986 Mar 22 |
|
Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate. | 1987 |
|
A comparison of two digestion procedures for the determination of selenium in biological material. | 1987 Oct |
|
Fluorimetry of selenium in body fluids after digestion with nitric acid, magnesium nitrate hexahydrate, and hydrochloric acid. | 1988 Sep |
|
[Hemiparesis and torsade de pointes under low-dose sotalol therapy]. | 1990 Sep 22 |
|
Magnesium and its combination with cinnarizine in the long-term treatment of headache. | 1991 |
|
Osteoporosis treated with magnesium lactate. | 1991 |
|
Oral versus intravenous magnesium supplementation in patients with magnesium deficiency. | 1991-1992 |
|
Management of eclampsia. | 1994 Apr |
|
Accidental cardiopulmonary arrest following magnesium sulphate overdose. | 1994 Jun 15 |
|
Effect of pyridoxine and magnesium on stress-induced gastric ulcers in mice selected for low or high blood magnesium levels. | 1995 |
|
Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity. | 1995 |
|
Inhibition of mouse-killing behaviour in magnesium-deficient rats: effect of pharmacological doses of magnesium pidolate, magnesium aspartate, magnesium lactate, magnesium gluconate and magnesium chloride. | 1995 Mar |
|
Conventional and Eccentric Uses of Crystallographic Databases in Practical Materials Identification Problems. | 1996 May-Jun |
|
Magnesium supplementation in patients with congestive heart failure. | 1997 Feb |
|
Struvite stones. | 1999 |
|
Effect of chronic magnesium supplementation on magnesium distribution in healthy volunteers evaluated by 31P-NMRS and ion selective electrodes. | 1999 Nov |
|
Some magnesium salts and a mixture of magnesium and calcium salts accelerate skin barrier recovery. | 1999 Oct |
|
Trifluoromethanesulfonic anhydride-promoted alpha-bromination of ketones with grignard reagent or magnesium bromide. | 2000 Dec |
|
An efficient chiral moderator prepared from inexpensive (+)-3-carene: synthesis of the HIV-1 non-nucleoside reverse transcriptase inhibitor DPC 963. | 2000 Oct 5 |
|
Bioavailability of US commercial magnesium preparations. | 2001 Dec |
|
Contraindication of magnesium sulfate in a pregnancy complicated with late-onset diabetes mellitus and sensory deafness due to mitochondrial myopathy. | 2001 Oct |
|
Magnesium bromide mediated highly diastereoselective heterogeneous hydrogenation of olefins. | 2002 Apr 18 |
|
Oral magnesium load test in patients with migraine. | 2002 Feb |
|
The prevention of pain from injection of rocuronium by magnesium sulphate, lignocaine, sodium bicarbonate and alfentanil. | 2003 Jun |
|
Synthesis of a non-heme template for attaching four peptides: an approach to artificial iron(II)-containing peroxidases. | 2004 Jan 23 |
|
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. | 2006 Apr |
|
Magnesium ions and opioid agonist activity in streptozotocin-induced hyperalgesia. | 2008 |
|
Formation of formal disilene fluoride adducts. | 2008 Dec 24 |
|
Neuronal activity and TrkB ligands influence Kv3.1b and Kv3.2 expression in developing cortical interneurons. | 2008 Oct 15 |
|
High dose magnesium sulfate exposure induces apoptotic cell death in the developing neonatal mouse brain. | 2009 |
|
Intradermal administration of magnesium sulphate and magnesium chloride produces hypesthesia to mechanical but hyperalgesia to heat stimuli in humans. | 2009 Aug 28 |
|
Galactosyl prodrug of ketorolac: synthesis, stability, and pharmacological and pharmacokinetic evaluations. | 2009 Jun 25 |
|
Cardiopulmonary arrest in pregnancy: two case reports of successful outcomes in association with perimortem Caesarean delivery. | 2009 Sep |
|
Cardiac effects of magnesium sulfate pretreatment on acute dichlorvos-induced organophosphate poisoning: an experimental study in rats. | 2010 Feb |
|
Increased expression of glucose transporter 3 in gerbil brains following magnesium sulfate treatment and focal cerebral ischemic injury. | 2010 Jun |
|
Effect of magnesium lactate dihydrate and calcium lactate monohydrate on 20-km cycling time trial performance. | 2012 Apr |
|
Magnesium chloride tetrahydrate, MgCl2·4H2O. | 2012 Jan |
|
[The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib]. | 2013 Jan-Feb |
|
No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia. | 2014 Apr-Jun |
|
Single-day sodium picosulfate and magnesium citrate versus split-dose polyethylene glycol for bowel cleansing prior to colonoscopy: A prospective randomized endoscopist-blinded trial. | 2015 Nov |
|
Micronized Organic Magnesium Salts Enhance Opioid Analgesia in Rats. | 2016 |
|
Polyethylene glycol plus ascorbic acid is as effective as sodium picosulfate with magnesium citrate for bowel preparation: A randomized trial. | 2016 Apr |
|
Preparation and optimization of a drug delivery system based on berberine chloride-immobilized MgAl hydrotalcite. | 2016 Jun 15 |
|
Superiority of a Split-dose Regimen of Sodium Picosulfate/Magnesium Citrate (SPMC) in Comparison to a Prior-day Schedule (AM/PM) for Colonoscopy Preparation. A Randomized Single-blinded Study. | 2016 Sep |
|
Fast sono assisted ferrofluid mediated silver super - Adsorption over magnesium ferrite-copper sulfide chalcogenide with the aid of multivariate optimization. | 2017 Jul |
|
Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes. | 2017 Mar 1 |
|
Antenatal Exposure to Magnesium Sulfate and Spontaneous Intestinal Perforation and Necrotizing Enterocolitis in Extremely Preterm Neonates. | 2017 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.standardprocess.com/Products/Standard-Process/Magnesium-Lactate#.WP-FxUXyizc https://www.drugs.com/mtm/magnesium-lactate.html http://en.remedy-info.com/magne-b6.html
Curator's Comment: Magnesium Chloride
Magnesium lactate is used as a dietary supplement (200-400 mg of elemental magnesium per day for adults).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:55 GMT 2025
by
admin
on
Mon Mar 31 18:09:55 GMT 2025
|
Record UNII |
02F3473H9O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QB05XA11
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
EPA PESTICIDE CODE |
13902
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
WHO-ATC |
B05XA11
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
WHO-ATC |
A12CC01
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-511
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
JECFA EVALUATION |
INS-511
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
CFR |
21 CFR 184.1426
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
||
|
WHO-VATC |
QA12CC01
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09407
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
SUB12526MIG
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
m6996
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
6636
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL2219642
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
7791-18-6
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
221118
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
13778-96-6
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
ALTERNATIVE | |||
|
02F3473H9O
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
C29240
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
100000091409
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
02F3473H9O
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
4200
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
SUB50141
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
24644
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
6579
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
ALTERNATIVE | |||
|
1374248
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
D015636
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
DTXSID0020789
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
86345
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
SUB20644
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY | |||
|
MAGNESIUM CHLORIDE
Created by
admin on Mon Mar 31 18:09:55 GMT 2025 , Edited by admin on Mon Mar 31 18:09:55 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|